Panacea Biotec
is one of India's leading research-based health management companies with
established research, manufacturing and marketing capabilities. Panacea Biotec
is the 2nd largest vaccine manufacturer in India. Panacea Biotec has been
ranked as the 3rd largest biotechnology company (ABLE Survey 2006) in India and
is also amongst the top 50 pharmaceutical companies in India.
Panacea Biotec has registered turnover of Rs. 5480 million during FY2006. The
product portfolio of the company includes highly innovative prescription
products in important therapeutic areas such as pain management, diabetes
management, cardiovascular management, renal-disease management, osteoporosis
management, anti-tubercular, gastro-intestinal care products and vaccines. The
company has collaborations and tie-ups with leading national and international
research organizations and corporations. The company's state of the art
manufacturing facilities comply with the US-FDA, UK-MHRA, SA-MCC and WHO-CGMP
standards. The company has four ultra modern, states - of - the - art research
and development centers. The company also has 10 international product patents.
The company has over 2300 employees including over 200 highly skilled
scientists
Panacea Biotec has developed several innovative vaccines.
The present portfolio of vaccines comprises of :
OPV ( poliomyelitis vaccine including monovalent Type
1 and 3 )
Enivac HB ( Inactivated hepatitis B Vaccine ) ,
Enivac HB Safsy,
Pentavalent Vaccines
Easy Five ( DTwP-HepB-Hib ) .
Panacea Biotec has
special focus in developing new products and novel drug delivery system for
vaccine(s) and therapeutic(s). Panacea Biotec is currently developing several
new generation vaccines
Vaccines under development are :
Anthrax vaccine (recombinant PA)
Avian Flu vaccine (recombinant)
CMV vaccine (recombinant)
RSV vaccine (recombinant)
Hepatitis A vaccine (recombinant)
Dengue Tetravalent vaccine (chimeric/recombinant)
Japanese Encephalitis vaccine (cell based)
For accelerating
innovation and growth, Panacea Biotec has undertaken effective alliances and
collaborations.
Some of the major alliances
and collaborations are:
Joint Venture with Chiron Corporation, US, to market new and
innovative breakthrough combination vaccines in India.
Collaboration with Cambridge Biostability Ltd., UK for
developing thermo stable vaccines, applying patented "Stable Liquid Technology.
An in-licensing arrangement with NRDC to manufacture and market
the Foot and Mouth Disease (FMD) vaccine developed by Indian Veterinary
Research Institute (IVRI).
An agreement with NVI (Nederland's Vaccine Institute
Netherlands) for manufacturing and marketing of Inactivated Polio Vaccine in
global markets except Netherlands, Denmark, Norway and Finland.
An agreement with PT. Bio Farma, Indonesia to manufacture &
market the Measles Vaccine and plans to supply the Vaccine to UNICEF, PAHO and
CIS, African, LATAM and Asian countries, in furtherance to the current WHO and
UNICEF Global Measles Reduction Strategy.
Moreover , In-licensing
arrangements with Biotechnology Consortium of India Ltd. (BCIL); National
Institutes of Health (NIH), USA and National Research Development Corporation
of India are some of its other vital strategic alliances done by Panacea
Biotec Ltd.For more information on our company please log on to
www.panacea-biotec.com
